var data={"title":"Epinephrine (adrenaline) (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Epinephrine (adrenaline) (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/791141?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=epinephrine-adrenaline-systemic-drug-information\" class=\"drug drug_general\">see &quot;Epinephrine (adrenaline) (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=epinephrine-adrenaline-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Epinephrine (adrenaline) (systemic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50306669\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pfizer Extended Expiration Dates for Emergency Syringe Shortages</span>\n      <span class=\"collapsible-date\">- updated November 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The FDA has alerted health care providers of extended expiration dates for certain injectable drug products manufactured by Hospira (a Pfizer company) which may be used beyond the labeled expiration dates to assist with the ongoing critical shortages of injectable drugs used in critical care. Select lot numbers of atropine sulfate injection, dextrose 50%, epinephrine injection, and sodium bicarbonate are eligible for use beyond the labeled expiration date if they have been and will continue to be stored according to the labeled conditions<b>. </b></p>\n        <p style=\"text-indent:0em;\">Further information, including specific products, lot numbers, and extended expiration dates, may be found at <a target=\"_blank\" href=\"https://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm563360.htm&amp;token=8RYIFfyLhIBYEqeX7m6uPGtnB1wPEGG5AqBctyC78FXNni9GZNAqH+dg03OunIQVFis/VBQ2KMfj5sKJ1X0d3K8AtSQsFLDSFqHlsS1NKKs=&amp;TOPIC_ID=105708\" target=\"_blank\">https://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm563360.htm</a><b>.</b></p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623785\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Adrenaclick [DSC];</li>\n      <li>Adrenalin;</li>\n      <li>Adyphren;</li>\n      <li>Adyphren Amp;</li>\n      <li>Adyphren Amp II;</li>\n      <li>Adyphren II;</li>\n      <li>Auvi-Q;</li>\n      <li>Epinephrinesnap-v;</li>\n      <li>EpiPen 2-Pak;</li>\n      <li>EpiPen Jr 2-Pak;</li>\n      <li>EPIsnap;</li>\n      <li>EPY II [DSC];</li>\n      <li>EPY [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623786\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Adrenalin;</li>\n      <li>Allerject;</li>\n      <li>Anapen;</li>\n      <li>Anapen Junior;</li>\n      <li>EpiPen;</li>\n      <li>EpiPen Jr;</li>\n      <li>Twinject</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45705702\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Adrenergic Agonist Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antidote, Hypersensitivity Reactions</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Bronchodilator</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Sympathomimetic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45705716\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> <b>As of May 1, 2016, ratio expressions of epinephrine concentrations are prohibited on drug labels. Ampules, vials, and syringes of epinephrine with ratio expressions may, however, remain in inventory until replaced by products with revised labeling. Therefore, the ratio expression of 1:1,000 is equivalent to 1 mg/mL and 1:10,000 is equivalent to 0.1 mg/mL (ISMP 2015).</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cardiopulmonary resuscitation</b> (Hegenbarth 2008; Kattwinkel 2010):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV, Intraosseous: 0.01 to 0.03 mg/kg (0.1 to 0.3 mL/kg of <b>0.1 mg/mL</b> solution) every 3 to 5 minutes as needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endotracheal: <b>Note:</b> IV route preferred: E.T.: 0.05 to 0.1 mg/kg (0.5 to 1 mL/kg of <b>0.1 mg/mL</b> solution) every 3 to 5 minutes until IV access established or return of spontaneous circulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypotension; fluid-refractory/dopamine resistant shock:</b> Limited data available: Premature and Term neonates: Continuous IV or intraosseous infusion: Initial: 0.05 to 0.3 mcg/kg/minute; usual range: 0.05 to 0.5 mcg/kg/minute; maximum reported dose: 2.6 mcg/kg/minute (ACCM [Davis 2017]; Heckmann 2002; Pellicer 2005; Valverde 2006). Dosing is based on a retrospective review of 31 neonates (GA: median: 26 weeks; range: 23 to 30 weeks) who received epinephrine doses ranging from 0.05 to 2.6 mcg/kg/minute; doses were titrated by 0.01 mcg/kg/minute as needed to stabilize mean blood pressure (Heckmann 2002). In another trial 60 neonates (GA: &lt;32 weeks) were randomized to receive epinephrine (n=32) or dopamine (n=28); doses were increased by 0.125 mcg/kg/minute every 20 minutes as needed to stabilize the mean blood pressure; epinephrine was found to be as effective as dopamine; however, patients receiving epinephrine experienced more transient adverse effects (eg, elevated serum lactate and glucose concentrations, increased requirement for bicarbonate and insulin administration) (Pellicer 2005; Valverde 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45705706\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=epinephrine-adrenaline-systemic-drug-information\" class=\"drug drug_general\">see &quot;Epinephrine (adrenaline) (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> <b>As of May 1, 2016, ratio expressions of epinephrine concentrations are prohibited on drug labels. Ampules, vials, and syringes of epinephrine with ratio expressions may, however, remain in inventory until replaced by products with revised labeling. Therefore, the ratio expression of 1:1,000 is equivalent to 1 mg/mL and 1:10,000 is equivalent to 0.1 mg/mL (ISMP 2015).</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asystole or pulseless arrest</b> (PALS [Kleinman 2010]): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV, I.O.: 0.01 mg/kg (0.1 mL/kg of <b>0.1 mg/mL</b> solution) (maximum single dose: 1 mg); every 3 to 5 minutes until return of spontaneous circulation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endotracheal: 0.1 mg/kg (0.1 mL/kg of <b>1 mg/mL</b> solution) (maximum single dose: 2.5 mg) every 3 to 5 minutes until return of spontaneous circulation or IV/I.O. access established. <b>Note:</b> Recent clinical studies suggest that lower epinephrine concentrations delivered by endotracheal administration may produce transient beta 2-adrenergic effects which may be detrimental (eg, hypotension, lower coronary artery perfusion pressure). IV or I.O. are the preferred methods of administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bradycardia</b> (PALS [Kleinman 2010]): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV, I.O.: 0.01 mg/kg (0.1 mL/kg of <b>0.1 mg/mL</b> solution) (maximum dose: 1 mg or 10 mL); may repeat every 3 to 5 minutes as needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endotracheal: 0.1 mg/kg (0.1 mL/kg of <b>1 mg/mL</b> solution) (maximum single dose: 2.5 mg); doses as high as 0.2 mg/kg may be effective; may repeat every 3 to 5 minutes as needed until IV/I.O. access established. <b>Note:</b> Recent clinical studies suggest that lower epinephrine concentrations delivered by endotracheal administration may produce transient beta 2-adrenergic effects which may be detrimental (eg, hypotension, lower coronary artery perfusion pressure). IV or I.O. are the preferred methods of administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cardiac output increase or maintenance/post-resuscitation stabilization: </b>Infants, Children, and Adolescents: Continuous IV or intraosseous infusion: 0.05 to 1 <b>mcg</b>/kg/<b>minute</b>; doses &lt;0.3 <b>mcg</b>/kg/<b>minute</b> generally produce beta-adrenergic effects and higher doses (&gt;0.3 <b>mcg</b>/kg/<b>minute</b>) generally produce alpha-adrenergic vasoconstriction; titrate dosage to desired effect (ACCM [Davis 2017]; PALS [Kleinman 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypersensitivity reaction/Anaphylaxis:</b> Infants, Children, and Adolescents: <b>Note:</b> The preferred route of administration is IM administration in the anterolateral aspect of the middle third of the thigh; SubQ administration results in slower absorption and is less reliable (Campbell 2014; Lieberman 2015; Simons 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>General dosing or health care settings: </i>IM, SubQ: 0.01 mg/kg (0.01 mL/kg/dose of <b>1 mg/mL</b> solution) not to exceed: Prepubertal child: 0.3 mg/dose; adolescent: 0.5 mg/dose; administered every 5 to 15 minutes (Hegenbarth 2008; Sicherer 2017; Simons 2011; Simons 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Self/caregiver-administration following severe allergic reactions (eg, insect stings, food):</i> Autoinjector dose: <b>Note:</b> If anaphylactic symptoms persist after first dose, may repeat dose in 5 to 15 minutes (Simons 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling (eg, Adrenaclik, Auvi-Q, EpiPen Jr, EpiPen): IM, SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">15 to 29 kg: 0.15 mg; if anaphylactic symptoms persist, dose may be repeated based on severity and response to initial dose; more than 2 sequential doses should only be administered under direct medical supervision</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;30 kg: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated based on severity and response to initial dose; more than 2 sequential doses should only be administered under direct medical supervision</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: AAP Recommendations (Sicherer 2017 ): Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">7.5 to &lt;25 kg: 0.15 mg</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">&ge;25 kg: 0.3 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Refractory cases (unresponsive to IM doses): </i>Continuous IV infusion: Prepared 1 <b>mcg</b>/mL solution: Initial: 0.1 <b>mcg</b>/kg/<b>minute</b>; titrate dose to response. Usual range: 0.1 to 1 <b>mcg</b>/kg/<b>minute</b>; maximum dose: 10 <b>mcg/minute </b>(Campbell 2014; Cheng 2011; Lieberman 2015). <b>Note:</b> Suggested concentration of initial solution is more dilute than those typically utilized in other clinical conditions; evaluate infusion concentration with continued therapy and patient fluid status.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypotension/shock, fluid-resistant:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion: 0.1 to 1 <b>mcg</b>/kg/<b>minute</b>; rates &gt;0.3 <b>mcg</b>/kg/<b>minute</b> associated with vasopressor activity; doses up to 5 mcg/kg/minute may rarely be necessary; for fluid-resistant shock, may be combined with inotropic support (ACCM [Davis 2017]; Hegenbarth 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: 0.01 mg/kg (0.01 mL/kg of <b>1 mg/mL</b> solution) (maximum single dose: 0.5 mg) every 20 minutes for 3 doses (Hegenbarth 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mydriasis during intraocular surgery, induction, and maintenance (product specific):</b> <b>Note:</b> Not all formulations of epinephrine injection are suitable for intraocular use; consult product labeling prior to use. Infants, Children, and Adolescents: Intraocular: Must dilute 1 mL of a 1 mg/mL preservative-/sulfite-free, single-use solution to a concentration of 1 <b>mcg</b>/mL to 10 <b>mcg</b>/mL prior to intraocular use: May use as an irrigation solution as needed during the procedure or may administer intracamerally (ie, directly into the anterior chamber of the eye) with a bolus dose of 0.1 mL of a 2.5 <b>mcg</b>/mL to 10 <b>mcg</b>/mL dilution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute severe asthma unresponsive to inhaled beta-agonist:</b> IM, SubQ: 0.01 mg/kg divided into 3 doses of ~0.3 to 0.5 mg every 20 minutes. <b>Note:</b> The <b>1 mg/mL</b> concentration is recommended (AHA [Vanden Hoek 2010]; Shah 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asystole/pulseless arrest, pulseless VT/VF </b> (ACLS [Neumar 2010]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV, I.O.: 1 mg every 3 to 5 minutes until return of spontaneous circulation; if this approach fails, higher doses of epinephrine (up to 0.2 mg/kg) have been used for treatment of specific problems (eg, beta-blocker or calcium channel blocker overdose); <b>Note:</b> High IV dose epinephrine (ie, &gt;1 mg per dose) has not been shown to improve survival or neurological outcomes as compared to standard dose epinephrine and is not recommended (ACLS [Neumar 2010]; ACLS [Neumar 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endotracheal: 2 to 2.5 mg every 3 to 5 minutes until IV/I.O. access established or return of spontaneous circulation; dilute in 5 to 10 mL NS or sterile water. <b>Note:</b> Absorption may be greater with sterile water (Naganobu 2000). May cause false-negative reading with exhaled CO<sub>2</sub> detectors; use second method to confirm tube placement if CO<sub>2</sub> is not detected (ACLS [Neumar 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bradycardia (symptomatic; unresponsive to atropine or pacing):</b> IV infusion: 2 to 10 mcg/minute <b>or</b> 0.1 to 0.5 mcg/kg/minute (7 to 35 mcg/minute in a 70 kg patient); titrate to desired effect (ACLS [Neumar 2010]; AHA [Peberdy 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypersensitivity reactions (eg, anaphylaxis): Note:</b> SubQ administration results in slower absorption and is less reliable. IM administration in the anterolateral aspect of the middle third of the thigh is preferred in the setting of anaphylaxis (AHA [Vanden Hoek 2010]; Kemp 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM (preferred), SubQ: 0.2 to 0.5 mg using the <b>1 mg/mL</b> solution every 5 to 15 minutes in the absence of clinical improvement (AAAAI [Lieberman 2015]; AHA [Vanden Hoek 2010]; Kemp 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Slow IV bolus:</i> 0.1 mg using the <b>0.1 mg/mL</b> solution (further diluted in 10 mL of NS) administered over 5 to 10 minutes (Barach 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Continuous IV infusion: </i>May initiate with an infusion at 2 to 15 mcg/minute (with crystalloid administration) (AAAAI [Lieberman 2015]; AHA [Vanden Hoek 2010]; Brown 2004). In general, IV administration should only be done in patients who are unresponsive or profoundly hypotensive who have failed to respond to IV fluid replacement and several epinephrine injections (Kemp 2008). If the patient is in in cardiopulmonary arrest, use of higher IV/IO push doses (ie, 1 mg every 3 to 5 minutes) should be employed or appropriate endotracheal doses administered if an advanced airway is in place (AAAAI [Lieberman 2015]; AHA [Neumar 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Self-administration following severe allergic reactions (eg, insect stings, food): <b>Note:</b> The World Health Organization (WHO) and Anaphylaxis Canada recommend the availability of one dose for every 10 to 20 minutes of travel time to a medical emergency facility. If anaphylactic symptoms persist after first dose, may repeat dose in 5 to 15 minutes (AHA [Vanden Hoek 2010]); more than 2 sequential doses should only be administered under direct medical supervision.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adrenaclick: IM, SubQ: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated using an additional Adrenaclick injector</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Auvi-Q: IM, SubQ: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">EpiPen: IM, SubQ: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated in 5 to 15 minutes using an additional EpiPen</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Symjepi: IM, SubQ: Weight &ge;30 kg: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypotension/shock:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i> Septic shock: IV infusion: Initial: 0.05 to 2 mcg/kg/minute (3.5 to 140 mcg/minute in a 70 kg patient); titrate to desired mean arterial pressure (MAP). May adjust dose every 10 to 15 minutes by 0.05 to 0.2 mcg/kg/minute to achieve desired blood pressure goal. After hemodynamic stabilization, may wean incrementally every 30 minutes over 12 to 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>American Heart Association recommendation:</i> Severe and fluid resistant: IV infusion: Initial: 0.1 to 0.5 mcg/kg/minute (7 to 35 mcg/minute in a 70 kg patient); titrate to desired response (AHA [Peberdy 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mydriasis during intraocular surgery, induction and maintenance (product specific):</b> <b>Note:</b> Not all formulations of epinephrine injection are suitable for intraocular use; consult product labeling. Intraocular: Must dilute 1 mL of a <b>1 mg/mL</b> single-use solution to a concentration of 1 to 10 <b>mcg</b>/mL prior to intraocular use: May use as an irrigation solution as needed during the procedure or may administer intracamerally (ie, directly into the anterior chamber of the eye) with a bolus dose of 0.1 mL of a 2.5 to 10 <b>mcg</b>/mL dilution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustment provided in manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustment provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623858\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Device, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EpiPen Jr 2-Pak: 0.15 mg/0.3 mL (2 ea) [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adyphren: 1 mg/mL [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adyphren Amp: 1 mg/mL [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adyphren Amp II: 1 mg/mL [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adyphren II: 1 mg/mL [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epinephrinesnap-v: 1 mg/mL [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EPIsnap: 1 mg/mL [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EPY: 1 mg/mL [DSC] [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EPY II: 1 mg/mL [DSC] [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adrenalin: 30 mg/30 mL (30 mL) [contains chlorobutanol (chlorobutol), disodium edta, sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (1 mL); 30 mg/30 mL (30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adrenalin: 1 mg/mL (1 mL) [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Auto-injector, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adrenaclick: 0.15 mg/0.15 mL (2 ea [DSC]); 0.3 mg/0.3 mL (2 ea [DSC]) [latex free; contains chlorobutanol (chlorobutol), sodium bisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Auvi-Q: 0.15 mg/0.15 mL (2 ea); 0.3 mg/0.3 mL (2 ea) [contains sodium bisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EpiPen 2-Pak: 0.3 mg/0.3 mL (2 ea) [contains sodium metabisulfite]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.15 mg/0.3 mL (1 ea, 2 ea); 0.15 mg/0.15 mL (1 ea [DSC], 2 ea); 0.3 mg/0.3 mL (1 ea, 2 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mcg/10 mL in NaCl 0.9% (10 mL); 200 mcg/10 mL in NaCl 0.9% (10 mL); 50 mcg/5 mL in NaCl 0.9% (5 mL); 500 mcg/10 mL in NaCl 0.9% (10 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623789\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50287478\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AUVI-Q 0.1 mg: FDA approved November 2017; availability anticipated in the first half of 2018. Consult prescribing information for additional information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Symjepi: FDA approved June 2017; anticipated availability currently undetermined</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45705708\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> <b>As of May 1, 2016, ratio expressions of epinephrine concentrations are prohibited on drug labels. Ampules, vials, and syringes of epinephrine with ratio expressions may, however, remain in inventory until replaced by products with revised labeling. Therefore, the ratio expression of 1:1,000 is equivalent to 1 mg/mL and 1:10,000 is equivalent to 0.1 mg/mL (ISMP 2015).</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endotracheal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: Use <b>0.1 mg/mL</b> solution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: Use <b>1 mg/mL</b> solution; administer and flush with a minimum of 5 mL NS, followed by 5 manual ventilations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intraocular: Administer as a diluted solution (concentration: 1 to 10 <b>mcg</b>/mL) as an irrigation solution as needed during the procedure or may administer intracamerally (ie, directly into the anterior chamber of the eye). <b>Note:</b> Not all formulations of epinephrine injection are suitable for intraocular use; consult the product labeling prior to use. Appropriate products should have mydriasis during intraocular surgery as an approved indication and should not contain any sulfites or preservatives (ISMP 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Direct IV or I.O. administration: If using <b>0.1 mg/mL</b> concentration, no dilution is necessary; the <b>1 mg/mL</b> concentration must be further diluted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion: When administering as a continuous infusion, central line administration is preferred. IV infusions require an infusion pump. If central line not available, as a temporary measure, may administer peripherally through a large vein. Avoid use of ankle veins (due to potential for gangrene), leg veins in those suffering from occlusive vascular diseases (eg, diabetic endarteritis, Buerger disease, arteriosclerosis, atherosclerosis).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Rate of infusion (mL/hour) = dose (mcg/kg/minute) x weight (kg) x 60 minutes/hour divided by the concentration (mcg/mL)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate phentolamine (or alternative antidote) (see Management of Drug Extravasations for more details). Apply dry warm compresses (Hurst 2004; Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM (eg, Auvi-Q, EpiPen, EpiPen Jr): Intramuscularly into anterolateral aspect of the middle third of the thigh is preferred in the setting of anaphylaxis (AAP [Sicherer 2017]); Kemp 2008; Lieberman 2015). Administer through clothing if necessary. Before administering to a child, immobilize leg to prevent laceration or other injury and consider restraining children who are likely to move during administration. Although the manufacturers of auto-injectors recommend varying lengths of time for holding the device in the thigh (range: 2 to 10 seconds), longer times have occasionally resulted in injury. For all devices, the needle should remain in the thigh for the least amount of time as possible. With nearly every device, the full dose is delivered within 3 seconds. For EpiPen, holding the device against the leg followed by removing the cap and then compressing has been described for easier administration. Never reinsert needles (Baker 2011; Brown 2016; Kr&auml;nke 2012; Lieberman 2011). Do not administer repeated injections at the same site. Do not inject into the buttocks or into digits, hands, or feet. Some products are single-use products and a new device should be used for each dose; consult product specific labeling. <b>Note:</b> In overweight or obese children, because skin surface to muscle depth is greater in the upper half of the thigh, administration into the lower half of the thigh may be preferred. In very obese children, injection into the calf will provide an even greater chance of intramuscular administration (Arkwright 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: Use only <b>1 mg/mL</b> solution. Although not preferred, if used for treatment of anaphylaxis, administer into the anterolateral aspect of the middle third of the thigh (Sicherer 2017)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623847\" class=\"block uicn drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 10 <b>mcg</b>/mL, 16 <b>mcg</b>/mL, 32 <b>mcg</b>/mL, or 64 <b>mcg</b>/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623848\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 16 <b>mcg</b>/mL, 32 <b>mcg</b>/mL, or 64 <b>mcg</b>/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623818\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Epinephrine is sensitive to light and air. Protection from light is recommended. Oxidation turns drug pink, then a brown color. <b>Solutions should not be used if they are discolored or contain a precipitate.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adrenaclick: Store between 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze or refrigerate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adrenalin: Store between 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do not freeze.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Allerject [Canadian product]: Store between 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not refrigerate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Auvi-Q: Store between 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not refrigerate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Epinephrine injection, USP: Store between 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do not refrigerate; protect from freezing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">EpiPen, EpiPen Jr, and Symjepi: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze or refrigerate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Twinject [Canadian product]: Store between 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze or refrigerate. Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Stability of injection of parenteral admixture at room temperature (25&deg;C) or refrigeration (4&deg;C) is 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45705703\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Treatment of type I allergic reactions including anaphylaxis (FDA approved in pediatric patients [age not specified] and adults); induction and maintenance of mydriasis during intraocular surgery (FDA approved in pediatric patients [age not specified] and adults; <b>Note:</b> Not all formulations of epinephrine injection are suitable for intraocular use; consult product labeling); treatment of hypotension associated with septic shock (increase mean arterial blood pressure) (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Autoinjectors (eg, Auvi-Q, EpiPen): Emergency treatment (immediate administration) of severe allergic reactions including anaphylaxis in patient at increased risk or previous history of anaphylactic reactions (FDA approved in patients weighing &ge;15 kg); <b>Note:</b> Minimum approved patient weight for some autoinjectors may vary (eg, 30 kg) based on product formulation (ie, mg dose delivered); consult product specific labeling</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623780\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">EPINEPHrine may be confused with ePHEDrine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epifrin may be confused with ephedrine, EpiPen</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Medication errors have occurred due to confusion with epinephrine products expressed as ratio strengths (eg, 1:1000 vs 1:10,000). </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epinephrine 1:1000 = 1 mg/mL and is most commonly used IM</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epinephrine 1:10,000 = 0.1 mg/mL and is used IV</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Medication errors have occurred when topical epinephrine 1 mg/mL (1:1000) has been inadvertently injected. Vials of injectable and topical epinephrine look very similar. Epinephrine should always be appropriately labeled with the intended administration. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">EpiPen [US, Canada, and multiple international markets] may be confused with Epigen brand name for glycyrrhizinic acid [Argentina, Mexico, Russia] and Epopen brand name for epoetin alfa [Spain] and Epigent brand name for gentamicin [multiple international markets] </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623809\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, cardiac arrhythmia, cardiomyopathy (stress), cerebrovascular accident, chest pain, hypertension, ischemic heart disease, limb ischemia, localized blanching, myocardial infarction, palpitations, supraventricular tachycardia, tachyarrhythmia, tachycardia, vasoconstriction, ventricular arrhythmia, ventricular ectopy, ventricular fibrillation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, apprehension, disorientation, dizziness, drowsiness, exacerbation of Parkinson disease, excitability, headache, memory impairment, nervousness, panic, paresthesia, psychomotor agitation, restlessness, tingling sensation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, gangrene of skin or other tissue (at injection site), pallor, piloerection, skin necrosis (with extravasation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperglycemia, hypoglycemia, hypokalemia, increased serum glucose (transient), insulin resistance, lactic acidosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Hemorrhage (CNS)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site tissue necrosis (including necrotizing fasciitis and myonecrosis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea, pulmonary edema, rales</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623804\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no absolute contraindications to the use of injectable epinephrine (including Adrenaclick, Auvi-Q, EpiPen, EpiPen Jr, Symjepi, Allerject [Canadian product], and Twinject [Canadian product]) in a life-threatening situation. Some products include the following contraindications: Hypersensitivity to sympathomimetic amines; general anesthesia with halogenated hydrocarbons (eg, halothane) or cyclopropane; narrow angle glaucoma; nonanaphylactic shock; in combination with local anesthesia of certain areas such as fingers, toes, and ears; use in situations where vasopressors may be contraindicated (eg, thyrotoxicosis, diabetes, in obstetrics when maternal blood pressure is in excess of 130/80 mm Hg and in hypertension and other cardiovascular disorders).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injectable solution (Adrenalin, Epinephrine injection, USP): There are no contraindications listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623805\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac effects: May precipitate or aggravate angina pectoris or induce cardiac arrhythmias; use with caution especially in patients with cardiac disease or those receiving drugs that sensitize the myocardium.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: IV administration: Vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary edema: Due to peripheral constriction and cardiac stimulation, pulmonary edema may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal effects: Due to renal blood vessel constriction, decreased urine output may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular diseases (eg, arrhythmias, cerebrovascular disease, coronary artery disease, heart disease, hypertension).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; may transiently increase blood glucose levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypovolemia: Correct blood volume depletion before administering any vasopressor.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Parkinson disease: Use with caution in patients with Parkinson disease; psychomotor agitation or temporary worsening of symptoms may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pheochromocytoma: Use with caution in patients with pheochromocytoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Use with caution in patients with thyroid disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Lacerations, bent needles, and embedded needles have been reported in young children who are uncooperative during injection for hypersensitivity reaction. To minimize risk, hold the child's leg firmly in place and limit movement prior to and during injection. Although the manufacturers of auto-injectors recommend varying lengths of time for holding the device in the thigh (range: 2 to 10 seconds), longer times have occasionally resulted in injury. For all devices, the needle should remain in the thigh for the least amount of time as possible (~3 seconds) (Brown 2016) (also see Administration: IM).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Accidental injection: Accidental injection into digits, hands, or feet may result in local reactions including injection-site pallor, coldness, and hypoesthesia or injury resulting in bruising, bleeding, discoloration, erythema, or skeletal injury. Patient should seek immediate medical attention if this occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intraocular use: Not all formulations of epinephrine injection are suitable for intraocular use; consult the prescribing information prior to selecting a product. Appropriate products should have an indication for induction and maintenance of mydriasis during intraocular surgery and should not contain any sulfites or preservatives (ISMP 2017). Prior to intraocular use of an appropriate product, must dilute single-use 1 mg/mL (1 mL) solution to a concentration of 1 <b>mcg</b>/mL to 10 <b>mcg</b>/mL. Corneal endothelial damage has occurred when products containing sodium bisulfite have been used undiluted; therefore, dilution is advised prior to any intraocular use. In addition, products containing chlorobutanol must also not be used intraocularly (may be harmful to corneal endothelium).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; IV administration: Rapid IV administration may cause death from cerebrovascular hemorrhage or cardiac arrhythmias. However, rapid IV administration during pulseless arrest is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfites: Some products may contain sulfites as preservatives. The presence of sulfites in some products should not deter administration during a serious allergic or other emergency situation even if the patient is sulfite-sensitive.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Hypersensitivity reactions: Do not inject into the buttock; may not effectively treat anaphylaxis and has been associated with Clostridial infections (gas gangrene). Serious skin and soft tissue infections, including necrotizing fasciitis and myonecrosis caused by Clostridia (gas gangrene), have been reported rarely at the injection site. Cleansing skin with alcohol may reduce bacteria at the injection site, but alcohol cleansing does not kill <i>Clostridium</i> spores. Preferred injection site is anterolateral aspect of the thigh. Do not administer repeated injections at the same site (tissue necrosis may occur). Monitor for signs/symptoms of injection-site infection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623814\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of COMT</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623811\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=105708&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Some beta-adrenoceptor mediated effects of Alpha-/Beta-Agonists (Direct-Acting), including anti-anaphylactic effects of epinephrine, may be diminished by Beta-Blockers. Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May diminish the therapeutic effect of EPINEPHrine (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloroprocaine: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: May diminish the therapeutic effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">COMT Inhibitors: May decrease the metabolism of COMT Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.<b> Exceptions: </b>Ergoloid Mesylates; Nicergoline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists.  Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalational Anesthetics: May enhance the arrhythmogenic effect of EPINEPHrine (Systemic). Management: Administer epinephrine with added caution in patients receiving, or who have recently received, inhalational anesthetics. Use lower than normal doses of epinephrine and monitor for the development of cardiac arrhythmias.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lurasidone: EPINEPHrine (Systemic) may enhance the hypotensive effect of Lurasidone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of EPINEPHrine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promethazine: May diminish the vasoconstricting effect of EPINEPHrine (Systemic). Management: When vasoconstrictive effects are desired in patients receiving promethazine, consider alternatives to epinephrine. Consider use of norepinephrine or phenylephrine, and avoid epinephrine, when treating hypotension associated with promethazine overdose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Management: Avoid, if possible, the use of direct-acting alpha-/beta-agonists in patients receiving tricyclic antidepressants. If combined, monitor for evidence of increased pressor effects and consider reductions in initial dosages of the alpha-/beta-agonist.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623800\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623801\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Epinephrine crosses the placenta (Sandler 1964). Uterine vasoconstriction, decreased uterine blood flow, and fetal anoxia may occur. Epinephrine is recommended for the treatment of anaphylaxis in pregnant women. Specific dosing is not available; use with caution and monitor hemodynamic response (Hepner 2013). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant woman. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (Jeejeebhoy [AHA] 2015). Although epinephrine injection may be used for asthma exacerbations in pregnancy, systemic therapy has not been proven to be better than use of preferred inhaled agents (NAEPP 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45705709\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">ECG, heart rate, blood pressure, site of infusion for excessive blanching/extravasation, cardiac monitor and blood pressure monitor required during continuous infusion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623822\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stimulates alpha-, beta<sub>1</sub>-, and beta<sub>2</sub>-adrenergic receptors resulting in relaxation of smooth muscle of the bronchial tree, cardiac stimulation (increasing myocardial oxygen consumption), and dilation of skeletal muscle vasculature; small doses can cause vasodilation via beta<sub>2</sub>-vascular receptors; large doses may produce constriction of skeletal and vascular smooth muscle</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623824\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Bronchodilation: SubQ: ~5 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Orally ingested doses are rapidly metabolized in GI tract and liver; pharmacologically active concentrations are not achieved</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Does not cross blood-brain barrier</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Taken up into the adrenergic neuron and metabolized by monoamine oxidase and catechol-o-methyltransferase; circulating drug hepatically metabolized</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IV: &lt;5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as inactive metabolites, metanephrine, and sulfate and hydroxy derivatives of mandelic acid, small amounts as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623860\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Adyphren Amp II Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1): $85.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Adyphren Amp Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1): $85.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Adyphren II Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1): $85.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Adyphren Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1): $85.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Epinephrinesnap-v Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1): $180.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (EPIsnap Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1): $156.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Adrenalin Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1 mL): $17.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg/30 mL (30 mL): $143.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (EPINEPHrine Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg/30 mL (30 mL): $70.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (EPINEPHrine PF Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1 mL): $2.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (Auvi-Q Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.15 mg/0.15 mL (2): $5,880.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg/0.3 mL (2): $5,880.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (EPINEPHrine Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.15 mg/0.15 mL (2): $494.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.15 mg/0.3 mL (1): $187.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg/0.3 mL (2): $375.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (EpiPen 2-Pak Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg/0.3 mL (2): $730.33</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (EpiPen Jr 2-Pak Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.15 mg/0.3 mL (2): $730.33</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (EPINEPHrine HCl-NaCl (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200MCG/10ML 0.9% (10 mL): $6.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (EPINEPHrine HCl-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50MCG/5ML 0.9% (5 mL): $10.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100MCG/10ML 0.9% (10 mL): $7.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500MCG/10ML 0.9% (10 mL): $7.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (EPINEPHrine PF Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/10 mL (10 mL): $5.47</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45855086\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adreject (CL);</li>\n      <li>Adreject Jr (CL);</li>\n      <li>Adrena (IN);</li>\n      <li>Adrenalin (BG, FI, TR);</li>\n      <li>Adrenalina (IT);</li>\n      <li>Adrenalina Sintetica (CH);</li>\n      <li>Adrenaline (RU);</li>\n      <li>Adrenaline Aguettant (FR);</li>\n      <li>Adrenalini Bitarticas (ID);</li>\n      <li>Adrenin (PH);</li>\n      <li>Ana-Guard (ZA);</li>\n      <li>Anapen (AT, CH, CY, CZ, DE, DK, EE, ES, FR, GR, HU, IE, LT, LU, LV, NL, PL, PT, SE, SG, SI);</li>\n      <li>Drenalin (BR);</li>\n      <li>Efrinalin (BR);</li>\n      <li>Ephedrix (PH);</li>\n      <li>Epifrin (BR);</li>\n      <li>Epifrina (CL, EC);</li>\n      <li>Epipen (AR, AT, AU, BB, BE, BG, CH, CZ, DK, EE, FI, FR, GB, GR, HK, HU, IE, IL, IS, LT, MT, NL, NO, NZ, PL, PT, RO, SE, SG, SI, SK, ZA);</li>\n      <li>Epipen Jr (AU);</li>\n      <li>Epipen Junior (BG, CZ, FI, GB, HK, IL, IS, MT, NL, NO, NZ, SE, SG, SK, TH);</li>\n      <li>Epix (PH);</li>\n      <li>Eppy (ZA);</li>\n      <li>Jext (AT, BE, CH, DK, ES, FI, FR, GB, NL, NO, SE, SK);</li>\n      <li>Phinev (ID);</li>\n      <li>Suprarenin (AT, DE);</li>\n      <li>Vascon (IN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adrenaclick (epinephrine systemic) [prescribing information]. Horsham, PA: Amedra; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adrenalin (epinephrine systemic) [prescribing information]. Chestnut Ridge, NY: Par Pharmaceuticals; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adrenalin (epinephrine systemic) solution [prescribing information]. Spring Valley, NY: Par Pharmaceuticals; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Auvi-Q (epinephrine systemic) [prescribing information ]. Richmond, VA: Kaleo, Inc.; May 2016</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arkwright P, Wright N, Bewick D, &ldquo;Anatomical and Anthropometric Determinants of Intramuscular versus Subcutaneous Administration in Children With Epinephrine Auto-injectors,&rdquo; <i>J Allergy Clin Immunol</i>, 2013, 131(2):AB199.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baker TW, Webber CM, Stolfi A, Gonzalez-Reyes E. The TEN study: time epinephrine needs to reach muscle. <i>Ann Allergy Asthma Immunol</i>. 2011;107(3):235-238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/21875542/pubmed\" target=\"_blank\" id=\"21875542\">21875542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barach EM, Nowak RM, Lee TG, Tomlanovich MC. Epinephrine for treatment of anaphylactic shock. <i>JAMA</i>. 1984;251(16):2118-2122.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/6708262/pubmed\" target=\"_blank\" id=\"6708262\">6708262</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brown JC, Tuuri RE, Akhter S, et al. Lacerations and embedded needles caused by epinephrine autoinjector use in children. <i>Ann Emerg Med</i>. 2016;67(3):307-315.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/26452720/pubmed\" target=\"_blank\" id=\"26452720\">26452720</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brown SG, Blackman KE, Stenlake V, et al, &quot;Insect Sting Anaphylaxis; Prospective Evaluation of Treatment With Intravenous Adrenaline and Volume Resuscitation,&quot; <i>Emerg Med J</i>, 2004, 21(2):149-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/14988337/pubmed\" target=\"_blank\" id=\"14988337\">14988337</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Campbell RL, Li JT, Nicklas RA, et al. Emergency department diagnosis and treatment of anaphylaxis: a practice parameter.<i> Ann Allergy Asthma Immunol</i>. 2014;113(6):599-608.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/25466802 /pubmed\" target=\"_blank\" id=\"25466802 \">25466802 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheng A. Emergency treatment of anaphylaxis in infants and children. <i>Paediatr Child Health</i>. 2011;16(1):35-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/22211074 /pubmed\" target=\"_blank\" id=\"22211074 \">22211074 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cydulka R, Davison R, Grammer L, Parker M, Mathews J 4th. The use of epinephrine in the treatment of older adult asthmatics. <i>Ann Emerg Med</i>. 1988;17(4):322-326.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/3354935/pubmed\" target=\"_blank\" id=\"3354935\">3354935</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davis AL, Carcillo JA, Aneja RK, et al. American College of Critical Care Medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. <i>Crit Care Med</i>. 2017;45(6):1061-1093.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/22211074 /pubmed\" target=\"_blank\" id=\"22211074 \">22211074 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. <i>Crit Care Med</i>. 2013;41(2):580-637.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/28509730/pubmed\" target=\"_blank\" id=\"28509730\">28509730</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Epinephrine injection [prescribing information]. Largo, FL: Belcher Pharmaceuticals; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    EpiPen/EpiPen Jr (epinephrine systemic) [prescribing information]. Morgantown, WV: Mylan Specialty LP; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122 (18 Suppl 3):640-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/20956217/pubmed\" target=\"_blank\" id=\"20956217\">20956217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heckmann M, Trotter A, Pohlandt F, Lindner W. Epinephrine treatment of hypotension in very low birthweight infants. <i>Acta Paediatr</i>. 2002;91(5):566-570.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/12113327 /pubmed\" target=\"_blank\" id=\"12113327 \">12113327 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA and the American Academy of Pediatrics Committee on Drugs, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo; <i>Pediatrics</i>, 2008, 121(2):433-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hepner DL, Castells M, Mouton-Faivre C, Dewachter P. Anaphylaxis in the clinical setting of obstetric anesthesia: a literature review. <i>Anesth Analg</i>. 2013;117(6):1357-1367.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/24257386 /pubmed\" target=\"_blank\" id=\"24257386 \">24257386 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hollenberg SM, Ahrens TS, Annane D, et al, &ldquo;Practice Parameters for Hemodynamic Support of Sepsis in Adult Patients: 2004 Update,&rdquo; <i>Crit Care Med</i>, 2004, 32(9):1928-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/15343024/pubmed\" target=\"_blank\" id=\"15343024\">15343024</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S and McMillan M, &ldquo;Innovative Solutions in Critical Care Units: Extravasation Guidelines,&rdquo; <i>Dimens Crit Care Nurs</i>, 2004, 23(3):125-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practices (ISMP). Acute care ISMP medication safety alert. December 3, 2015, 20(24).</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, &ldquo;Standard Concentrations of Neonatal Drug Infusions,&rdquo; 2011. Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practice (ISMP). Acute Care ISMP Medication Safey Alert. June 15, 2017 (22:12).</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kattwinkel J, Perlman JM, Aziz K, et al. Neonatal resuscitation: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Pediatrics</i>. 2010;126(5):e1400-1413.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/20956432 /pubmed\" target=\"_blank\" id=\"20956432 \">20956432 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kemp SF, Lockey RF, Simons FE, et al, &ldquo;Epinephrine: The Drug of Choice for Anaphylaxis. A Statement of the World Allergy Organization,&rdquo; <i>Allergy</i>, 2008, 63(8):1061-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/18691308/pubmed\" target=\"_blank\" id=\"18691308\">18691308</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al, &ldquo;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kr&auml;nke B, Schuster C, Wiednig M, Reiter H. A simple method to improve safety of epinephrine auto-injectors. <i>Pediatr Allergy Immunol</i>. 2012;23(4):399-400.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/22594931/pubmed\" target=\"_blank\" id=\"22594931\">22594931</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. <i>Ann Allergy Asthma Immunol</i>. 2015;115(5):341-384.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/21875535/pubmed\" target=\"_blank\" id=\"21875535\">21875535</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieberman P. The 10-second rule and other myths about epinephrine and autoinjectors. <i>Ann Allergy Asthma Immunol</i>. 2011;107(3):189-190.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/26505932 /pubmed\" target=\"_blank\" id=\"26505932 \">26505932 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naganobu K, Hasebe Y, Uchiyama Y, et al, &ldquo;A Comparison of Distilled Water and Normal Saline as Diluents for Endobronchial Administration of Epinephrine in the Dog,&rdquo; <i>Anesth Analg</i>, 2000, 91(2):317-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/10910841/pubmed\" target=\"_blank\" id=\"10910841\">10910841</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Otto CW, Link MS, et al, &ldquo;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):729-67.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Shuster M, Callaway CW, et al. Part 1: executive summary: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2015;132(18 Suppl 2):S315-S367.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/26472989 /pubmed\" target=\"_blank\" id=\"26472989 \">26472989 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peberdy MA, Callaway CW, Neumar RW, et al, &ldquo;Part 9: Post Cardiac Arrest Care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):768-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/20956225/pubmed\" target=\"_blank\" id=\"20956225\">20956225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pellicer A, Valverde E, Elorza MD, et al. Cardiovascular support for low birth weight infants and cerebral hemodynamics: a randomized, blinded, clinical trial. <i>Pediatrics</i>. 2005;115(6):1501-1512.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/15930210 /pubmed\" target=\"_blank\" id=\"15930210 \">15930210 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/24420913/pubmed\" target=\"_blank\" id=\"24420913\">24420913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rotta AT, Wiryawan B. Respiratory emergencies in children. <i>Respir Care</i>. 2003;48(3):248-258.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/12667275/pubmed\" target=\"_blank\" id=\"12667275\">12667275</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shah R, Saltoun CA. Chapter 14: Acute severe asthma (status asthmaticus). <i>Allergy Asthma Proc</i>. 2012;33(Suppl 1):S47-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/12667275/pubmed\" target=\"_blank\" id=\"12667275\">12667275</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sicherer SH, Simons FER; Section on Allergy and Immunology. Epinephrine for first-aid management of anaphylaxis.<i> Pediatrics</i>. 2017;139(3).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/28193791/pubmed\" target=\"_blank\" id=\"28193791\">28193791</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simons FE, Ardusso LR, Bil&ograve; MB, et al. World allergy organization guidelines for the assessment and management of anaphylaxis. <i>World Allergy Organ J</i>. 2011;4(2):13-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/23268454/pubmed\" target=\"_blank\" id=\"23268454\">23268454</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simons FE, Ebisawa M2, Sanchez-Borges M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organ J. 2015 Oct 28;8(1):32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/26525001/pubmed\" target=\"_blank\" id=\"26525001\">26525001</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Symjepi injection (epinephrine systemic) [prescribing information]. San Diego, CA: Adamis Pharmaceuticals Corporation; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trissel LA. <i>Handbook on Injectable Drugs</i>. 18th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Valverde E, Pellicer A, Madero R, Elorza D, Quero J, Caba&ntilde;as F. Dopamine versus epinephrine for cardiovascular support in low birth weight infants: analysis of systemic effects and neonatal clinical outcomes. <i>Pediatrics</i>. 2006;117(6):e1213-1222.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/16717120/pubmed\" target=\"_blank\" id=\"16717120\">16717120</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanden Hoek TL, Morrison LJ, Shuster M, et al, &ldquo;Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):829-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epinephrine-adrenaline-systemic-pediatric-drug-information/abstract-text/20956228/pubmed\" target=\"_blank\" id=\"20956228\">20956228</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 105708 Version 83.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50306669\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F45623785\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F45623786\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F45705702\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F45705716\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F45705706\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F45623858\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F45623789\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50287478\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F45705708\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Neonatal\" href=\"#F45623847\" class=\"outlineLink\">Usual Infusion Concentrations: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F45623848\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F45623818\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F45705703\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F45623780\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F45623809\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F45623804\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F45623805\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F45623814\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F45623811\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F45623800\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F45623801\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F45705709\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F45623822\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F45623824\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F45623860\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45855086\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/105708|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=epinephrine-adrenaline-systemic-drug-information\" class=\"drug drug_general\">Epinephrine (adrenaline) (systemic): Drug information</a></li><li><a href=\"topic.htm?path=epinephrine-adrenaline-systemic-patient-drug-information\" class=\"drug drug_patient\">Epinephrine (adrenaline) (systemic): Patient drug information \t</a></li></ul></div></div>","javascript":null}